Intuitive Surgical, a major Silicon Valley medtech company, has paused H-1B visa sponsorship offers due to the recent $100,000 fee policy implemented by the Trump administration, reflecting broader impacts on tech industry hiring practices amid immigration policy changes.
Intuitive Surgical's stock surged after receiving FDA clearance for its next-generation robotic surgery system, da Vinci 5, which promises improved accuracy, precision, and computing power compared to its predecessor, da Vinci Xi. The company plans to initially launch the system for a small number of U.S. surgeons before a broader release, aiming to gather additional data on its use. CEO Gary Guthart anticipates that the new system will lead to better patient outcomes, enhanced experiences for both patients and care teams, and reduced overall healthcare costs.
Intuitive, a leader in minimally invasive care, has received FDA clearance for its fifth-generation robotic system, da Vinci 5, designed to enhance surgical precision and patient outcomes. The system features improvements such as next-generation 3D display, force-sensing technology, and enhanced computing power, aiming to streamline workflow and increase surgeon comfort. Initially available to select U.S. customers, da Vinci 5 builds on the success of its predecessors and is expected to drive the future of robotic-assisted surgery.
A man is suing Intuitive Surgical, the maker of the da Vinci surgical robot, alleging that the robot burned and tore his wife's small intestine during surgery, leading to her death. The lawsuit claims that the company received numerous reports of injuries and defects related to the robot, and that it underreported the severity of these injuries to the FDA. The plaintiff is seeking damages and relief on the grounds of negligence and product liability.
A wrongful death lawsuit alleges that a woman's small intestine was burned and torn by a robotic device during surgery for colon cancer, leading to her death. The lawsuit claims that the maker of the device, Intuitive Surgical, knew about insulation problems that could cause electricity to leak and burn internal organs but didn't disclose the risk. Intuitive Surgical has faced previous lawsuits and FDA warnings related to its da Vinci robot, with reports of injuries and deaths associated with the device.
Intuitive Surgical has submitted for FDA clearance of its next-generation da Vinci 5 multiport surgical robot, with hopes for a 2024 launch. The company reported strong Q4 results, with revenue up 17% year-over-year. The da Vinci 5 will join Intuitive’s existing robotic surgical system portfolio, and the company is also in discussions with regulators in Japan and South Korea. Intuitive is gearing up for da Vinci 5 manufacturing and promises more details about its features and benefits after FDA clearance.
Stock futures fluctuated as Wall Street awaited U.S. inflation data and the start of corporate earnings season, with Juniper, Coinbase, Intuitive Surgical, Aehr Test Systems, Toast, and Smart Global among the stocks moving the most.
Intuitive Surgical, a leading robotic surgery company, reported better-than-expected third-quarter profit but fell short on sales, causing its stock to plummet. While the company saw a 19% growth in the number of procedures using its da Vinci robotic surgery systems, sales missed forecasts. The stock drop comes amid pressure from competitors in the bariatric surgery field and uncertainty in the market.
Intuitive Surgical reported better-than-expected sales and profit for the second quarter, but its stock fell as the number of installed da Vinci robotic surgery systems fell short of forecasts. The company's installed base increased by 12.5% to 8,042 globally, missing expectations of 8,203. Despite this, sales rose 15% to $1.76 billion, beating predictions, and adjusted profit increased by nearly 25% to $1.42 per share. Procedures using the da Vinci systems increased by 22%, contributing to strong sales of instruments and accessories.
Intuitive Surgical's Q1 revenue grew 14% YoY to $1.7 billion, beating Wall Street estimates, as patients returned to healthcare providers post-COVID and hospitals used robotic-assisted procedures for minimally invasive surgeries. The company raised its 2023 procedure growth guidance from 12-16% to 18-21%. Most analysts are bullish on the stock, with 15 Buy ratings, 14 Hold, and 1 Sell.
The stock market was slightly lower at midday on Wednesday, with investors focusing on earnings reports from major companies such as Netflix and Morgan Stanley. Nasdaq 100 stock Intuitive Surgical soared after beating earnings expectations, while payment processing firm Shift4 plunged, hurting the IBD 50 index. The 10-year Treasury yield rose to 3.63%. After the market close, IBM, Lam Research, and Steel Dynamics are among the notable companies reporting earnings.
Netflix shares gained less than 1% after posting a beat on per-share earnings but falling short of Wall Street's revenue estimates. Interactive Brokers' shares pulled back 4% after reporting adjusted earnings per share of $1.35, below a consensus estimate of $1.41. Western Alliance Bancorp's regional bank popped nearly 15% despite revenues coming in at $552 million, compared to the $666 million anticipated by analysts. Intuitive Surgical shares added 8% after posting an earnings beat with revenue coming in ahead of expectations at $1.70 billion. United Airlines gained 1.3% on forward guidance in the company's latest earnings report that forecasts a second-quarter profit.
Intuitive Surgical, the leader in robotic surgery, reported a 26% surge in procedures completed using its da Vinci system during the first quarter of 2021, beating expectations and pushing ISRG stock up 8.8%. Revenue from instruments and accessories climbed 22% to $986 million, driven by the strong increase in da Vinci procedures. Despite Covid-19 negatively impacting procedure volumes in China, Intuitive Surgical's overall revenue jumped 14% to $1.7 billion.